Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
+603 2381 8700
Submit a Proposal


Advanced drug particle design

Liquidia’s (NASDAQ:LQDA) proprietary nanoparticle (PRINT) technology is a novel fabrication process capable of precisely engineering drug particles to control their size, shape and chemical composition. The PRINT process optimises drug formulation to enhance the performance of existing and new therapies and can be applied to virtually any therapeutic area, molecule or route of administration. It provides the pharmaceutical industry the power to produce more stable, clinically effective products at scale and reduce manufacturing complexity and cost.


Liquidia's proprietary PRINT® engineering technology allows us to engineer and manufacture highly uniform drug particles with precise control over the size, three-dimensional geometric shape and chemical composition of the particles.

  • Founded


  • Partnered


  • IPO

    2018 (LQDA)

View Website
Let's talk

Are you the next big thing?

We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!